# Bone Mineral Density in Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Adult Subjects Switching From a Tenofovir Regimen to a Dolutegravir Plus Rilpivirine Regimen

> **NCT02478632** · PHASE3 · COMPLETED · sponsor: **ViiV Healthcare** · enrollment: 102 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Subjects do not receive study medication in this study 202094

## Key facts

- **NCT ID:** NCT02478632
- **Lead sponsor:** ViiV Healthcare
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06-12
- **Primary completion:** 2016-09-16
- **Final completion:** 2018-08-17
- **Target enrollment:** 102 (ACTUAL)
- **Last updated:** 2020-10-19

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02478632

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02478632, "Bone Mineral Density in Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Adult Subjects Switching From a Tenofovir Regimen to a Dolutegravir Plus Rilpivirine Regimen". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02478632. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*